NCT02965001View on ClinicalTrials.gov

Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Head and Neck Cancer
Interventions
DRUG

68Ga-NOTA-AE105

The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.

Trial Locations (1)

2100

Departmen of Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen University Hospital, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT02965001 - Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer | Biotech Hunter | Biotech Hunter